Histology and Cytology Market to Reach $22.2 Billion Globally By 2032 | CAGR of 11.9% CAGR

Allied Market Research published a report, titled, "Histology and Cytology Market by Type of Examination (Histology and Cytology), Product (Instruments & Analysis Software System and Consumable & Reagents), Test Type (Microscopy Methods, Flow Cytometry, and Molecular Genetic Methods), Application (Drug Discovery & Designing, Clinical Diagnostics, and Academic Research), and End User (Pharma & Biotech Companies, CDMO, Diagnostic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global histology and cytology market generated $7.2 billion in 2022, and is anticipated to generate $22.2 billion by 2032, witnessing a CAGR of 11.9% from 2023 to 2032.

Prime Determinants of Growth

The histology and cytology market is expected to witness notable growth owing to rising prevalence of chronic diseases, growing pharmaceutical industry in developing region, and improving healthcare infrastructure. Moreover, technological advancement in histological and cytological analysis technology is expected to provide lucrative opportunity for the growth of the market during the forecast period. On the contrary, high cost of histological and cytological analytical instruments limits the growth of the market.

Request Sample of the Report on -

https://www.alliedmarketresearch.com/request-sample/A15397

Recession Impact

During a recession, governments and healthcare organizations often face budget constraints, leading to a reduction in healthcare spending. This affects funding for medical research, including histology and cytology studies, and results in delayed adoption of advanced technologies.
Economic downturns have led to reduced discretionary spending by individuals, impacting their ability to afford regular health check-ups and screening procedures. As a result, there was a decline in the number of histological and cytological examinations performed.
Healthcare institutions postponed or scaled back capital expenditures during recession. This affected the acquisition of new histology and cytology equipment, slowing down the adoption of advanced technologies in laboratories.
Research funding from both public and private sources decrease during economic downturns. This reduction in funding could affect histology and cytology research projects, potentially slowing down the development of innovative diagnostic tools and methodologies.
The cytology segment to maintain its leadership status throughout the forecast period

By type of examination, the cytology segment held the largest share in 2022, accounting for more than two-thirds of the histology and cytology market revenue and is estimated to be the fastest growing segment during the forecast period. This growth is attributed to the high adoption of the cytological techniques in the disease diagnosis. Cytology plays a crucial role in early detection and diagnosis of various cancers, such as cervical, breast, and lung cancers.

The consumables and reagents segment to maintain its lead position during the forecast period

By product, the consumables and reagents segment held the largest share in 2022, accounting for almost three-fifths of the histology and cytology market revenue. This growth is attributed to the fact that the consumables and reagents are used in almost every histological and cytological procedures. The reagents such as stanning agents play crucial role in improving the visibility of the cell organs. However, instruments and analysis software system segment are expected to register the highest CAGR during the forecast period, owing to technological advancements in the histological and cytological instruments and growing trends toward laboratory automation.

The microscopy methods segment to maintain its lead position during the forecast period

By test type, the microscopy methods segment accounted for the largest share in 2022, accounting for almost three-fifths of the histology and cytology market revenue. This is attributed to the fact that microscopic method of analysis is cost efficient and thus is adopted by large number of medium and small-scale diagnostic laboratory. However, flow cytometry segment is expected to register highest CAGR during the forecast period owing to high adoption of flow cytometry instrument by pharmaceutical and biotechnology companies.

The drug discovery and designing segment to maintain its lead position during the forecast period

By application, the drug discovery and designing segment accounted for the largest share in 2022, accounting for more than half of the histology and cytology market revenue. This is attributed to the histological and cytological analysis being the crucial evaluation parameter of new drug development. However, academic research segment is expected to register the highest CAGR during the forecast period owing to rise in research and development in the field of cytology and histology and surge in number of students choosing histology or cytology as their educational programs and career.

The pharma and biotech companies segment to maintain its lead position during the forecast period

By end user, the pharma and biotech companies segment accounted for the largest share in 2022, accounting for more than one-third of the histology and cytology market revenue owing to high adoption of histological and cytological testing in preclinical trials of new drug. However, CDMO segment is expected to register highest CAGR during the forecast period owing to growing trend of outsourcing the research and development activities in the pharmaceutical sector.

North America to maintain its dominance by 2032

By region, North America held the largest market share in terms of revenue in 2022, accounting for nearly two-fifths of the global histology and cytology market revenue and is likely to dominate the market during the forecast period.

This is attributed to the rising healthcare expenditure, aging population, and increasing awareness of early diagnosis technological advancements in diagnostic instruments.

However, Asia-Pacific is projected to register the fastest growth during the forecast period, owing to increase in prevalence of chronic diseases, including cancer, cardiovascular diseases, and others. This prevalence creates a sustained demand for histology and cytology instruments for diagnosis and research purposes, which further drives the market growth in the region.

For Procurement Information - https://www.alliedmarketresearch.com/purchase-enquiry/A15397

Leading Market Players

Hologic, Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Becton, Dickinson and Company
Danaher Corporation
Merck KGaA
Thermo Fisher Scientific, Inc.
Sysmex Corporation
Trivitron Healthcare Private Limited
Koninklijke Philips N.V.

Contact :

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

This release was published on openPR.